Stephanie P Hao1, Elysia A Masters1,2, Mark J Ninomiya1, Christopher A Beck3, Edward M Schwarz1,2,4, John L Daiss1,4, Irvin Oh1,4. 1. Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA. 2. Department of Biomedical Engineering, University of Rochester Medical Center, Rochester, NY, USA. 3. Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USA. 4. Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center, Rochester, NY, USA.
Abstract
BACKGROUND: Conventional bacterial cultures frequently fail to identify the dominant pathogen in polymicrobial foot infections, in which Staphylococcus aureus is the most common infecting pathogen. Previous work has shown that species-specific immunoassays may be able to identify the main pathogen in musculoskeletal infections. We sought to investigate the clinical applicability of a S. aureus immunoassay to accurately identify the infecting pathogen and monitor its infectivity longitudinally in foot infection. We hypothesized that this species-specific immunoassay could aid in the diagnosis of S. aureus and track the therapeutic response in foot infections. METHODS: From July 2015 to July 2019, 83 infected foot ulcer patients undergoing surgical intervention (debridement or amputation) were recruited and blood was drawn at 0, 4, 8, and 12 weeks. Whole blood was analyzed for S. aureus-specific serum antibodies (mix of historic and new antibodies) and plasmablasts were isolated and cultured to quantify titers of newly synthesized antibodies (NSAs). Anti-S. aureus antibody titers were compared with culture results to assess their concordance in identifying S. aureus as the pathogen. The NSA titer changes at follow-ups were compared with wound healing status to evaluate concordance between evolving host immune response and clinically resolving or relapsing infection. RESULTS: Analysis of serum for anti-S. aureus antibodies showed significantly increased titers of 3 different anti-S. aureus antibodies, IsdH (P = .037), ClfB (P = .025), and SCIN (P = .005), in S. aureus culture-positive patients compared with culture-negative patients. Comparative analysis of combining antigens for S. aureus infection diagnosis increased the concordance further. During follow-up, changes of NSA titers against a single or combination of S. aureus antigens significantly correlated with clinically resolving or recurring infection represented by wound healing status. CONCLUSION: In the management of foot infection, the use of S. aureus-specific immunoassay may aid in diagnosis of the dominant pathogen and monitoring of the host immune response against a specific pathogen in response to treatment. Importantly, this immunoassay could detect recurrent foot infection, which may guide a surgeon's decision to intervene. LEVEL OF EVIDENCE: Level II, prospective comparative study.
BACKGROUND: Conventional bacterial cultures frequently fail to identify the dominant pathogen in polymicrobial foot infections, in which Staphylococcus aureus is the most common infecting pathogen. Previous work has shown that species-specific immunoassays may be able to identify the main pathogen in musculoskeletal infections. We sought to investigate the clinical applicability of a S. aureus immunoassay to accurately identify the infecting pathogen and monitor its infectivity longitudinally in foot infection. We hypothesized that this species-specific immunoassay could aid in the diagnosis of S. aureus and track the therapeutic response in foot infections. METHODS: From July 2015 to July 2019, 83 infected foot ulcer patients undergoing surgical intervention (debridement or amputation) were recruited and blood was drawn at 0, 4, 8, and 12 weeks. Whole blood was analyzed for S. aureus-specific serum antibodies (mix of historic and new antibodies) and plasmablasts were isolated and cultured to quantify titers of newly synthesized antibodies (NSAs). Anti-S. aureus antibody titers were compared with culture results to assess their concordance in identifying S. aureus as the pathogen. The NSA titer changes at follow-ups were compared with wound healing status to evaluate concordance between evolving host immune response and clinically resolving or relapsing infection. RESULTS: Analysis of serum for anti-S. aureus antibodies showed significantly increased titers of 3 different anti-S. aureus antibodies, IsdH (P = .037), ClfB (P = .025), and SCIN (P = .005), in S. aureus culture-positive patients compared with culture-negative patients. Comparative analysis of combining antigens for S. aureus infection diagnosis increased the concordance further. During follow-up, changes of NSA titers against a single or combination of S. aureus antigens significantly correlated with clinically resolving or recurring infection represented by wound healing status. CONCLUSION: In the management of foot infection, the use of S. aureus-specific immunoassay may aid in diagnosis of the dominant pathogen and monitoring of the host immune response against a specific pathogen in response to treatment. Importantly, this immunoassay could detect recurrent foot infection, which may guide a surgeon's decision to intervene. LEVEL OF EVIDENCE: Level II, prospective comparative study.
Authors: Edward M Schwarz; Javad Parvizi; Thorsten Gehrke; Amiethab Aiyer; Andrew Battenberg; Scot A Brown; John J Callaghan; Mustafa Citak; Kenneth Egol; Grant E Garrigues; Michelle Ghert; Karan Goswami; Andrew Green; Sommer Hammound; Stephen L Kates; Alex C McLaren; Michael A Mont; Surena Namdari; William T Obremskey; Robert O'Toole; Steven Raikin; Camilo Restrepo; Benjamin Ricciardi; Kordo Saeed; Joaquin Sanchez-Sotelo; Noam Shohat; Timothy Tan; Caroline P Thirukumaran; Brian Winters Journal: J Orthop Res Date: 2019-04-25 Impact factor: 3.494
Authors: Benjamin A Lipsky; Anthony R Berendt; Paul B Cornia; James C Pile; Edgar J G Peters; David G Armstrong; H Gunner Deery; John M Embil; Warren S Joseph; Adolf W Karchmer; Michael S Pinzur; Eric Senneville Journal: Clin Infect Dis Date: 2012-06 Impact factor: 9.079
Authors: Irvin Oh; Gowrishankar Muthukrishnan; Mark J Ninomiya; James D Brodell; Benjamin L Smith; Charles C Lee; Steven R Gill; Christopher A Beck; Edward M Schwarz; John L Daiss Journal: Infect Immun Date: 2018-11-20 Impact factor: 3.441
Authors: R J Molines-Barroso; J L Lázaro-Martínez; J Aragón-Sánchez; E García-Morales; J V Beneit-Montesinos; F J Álvaro-Afonso Journal: Diabet Med Date: 2013-04-20 Impact factor: 4.359
Authors: Elysia A Masters; Ryan P Trombetta; Karen L de Mesy Bentley; Brendan F Boyce; Ann Lindley Gill; Steven R Gill; Kohei Nishitani; Masahiro Ishikawa; Yugo Morita; Hiromu Ito; Sheila N Bello-Irizarry; Mark Ninomiya; James D Brodell; Charles C Lee; Stephanie P Hao; Irvin Oh; Chao Xie; Hani A Awad; John L Daiss; John R Owen; Stephen L Kates; Edward M Schwarz; Gowrishankar Muthukrishnan Journal: Bone Res Date: 2019-07-15 Impact factor: 13.567